Research
Hormonal
Ectopic fat accumulation in non-adipose tissues (liver, muscle, pancreas) drives insulin resistance and organ dysfunction through lipotoxicity, mediated by toxic lipid derivatives like diacylglycerol (DAG) and ceramides.
Excess fat stored in organs like the liver and muscles is dangerous because it produces toxic byproducts that block insulin. Managing overall caloric intake and increasing physical activity can help reduce this ectopic fat and improve metabolic health.
GoodSupportsHIGH confidence
Consequent to the limited ability of non-adipose tissue to oxidize and/or to store FFA, ectopic accumulation of FFA and/or its metabolic active derivatives would lead to IR as well as cell lipotoxicity and apoptosis compromising the function of the involved organs.
Why this rating
The paper details specific molecular pathways (DAG, ceramides) linking ectopic fat to IR, supported by multiple references.
Source
Obesity, insulin resistance and comorbidities ? Mechanisms of association
Ana Valeria Castro et al. · Arquivos Brasileiros de Endocrinologia & Metabologia · 2014
DOI 10.1590/0004-2730000003223
narrative_reviewCited 253×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Visceral adipose tissue (VAT) and ectopic fat accumulation are stronger predictors of insulin resistance and metabolic comorbidities than total body fat mass (BMI), primarily due to increased lipolysis, free fatty acid (FFA) spillover, and inflammatory cytokine secretion.Good
- Peripheral adiposity (large hip and thigh circumference) is associated with a better metabolic profile, including better glucose tolerance and reduced incidence of type 2 diabetes, compared to central/visceral adiposity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →